330 related articles for article (PubMed ID: 21814873)
1. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
2. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
[TBL] [Abstract][Full Text] [Related]
3. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
5. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
Ellard S; Colclough K
Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
[TBL] [Abstract][Full Text] [Related]
7. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
Pihoker C; Gilliam LK; Ellard S; Dabelea D; Davis C; Dolan LM; Greenbaum CJ; Imperatore G; Lawrence JM; Marcovina SM; Mayer-Davis E; Rodriguez BL; Steck AK; Williams DE; Hattersley AT;
J Clin Endocrinol Metab; 2013 Oct; 98(10):4055-62. PubMed ID: 23771925
[TBL] [Abstract][Full Text] [Related]
9. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
Liu J; Xiao X; Zhang Q; Yu M
J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
[TBL] [Abstract][Full Text] [Related]
10. RD Lawrence lecture 2012: assessing aetiology in diabetes: how C-peptide, CRP and fucosylation came to the party!
Owen KR
Diabet Med; 2013 Mar; 30(3):260-6. PubMed ID: 23106207
[TBL] [Abstract][Full Text] [Related]
11. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
Thanabalasingham G; Pal A; Selwood MP; Dudley C; Fisher K; Bingley PJ; Ellard S; Farmer AJ; McCarthy MI; Owen KR
Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
[TBL] [Abstract][Full Text] [Related]
12. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young.
Wang X; Wang T; Yu M; Zhang H; Ping F; Zhang Q; Xu J; Feng K; Xiao X
Acta Diabetol; 2019 Mar; 56(3):281-288. PubMed ID: 30293189
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing the lipid profile of GCK-MODY patients and its correlation with hsCRP levels.
Ping F; Fu J; Xiao X
Front Endocrinol (Lausanne); 2022; 13():1024431. PubMed ID: 36387841
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
[TBL] [Abstract][Full Text] [Related]
16. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
[TBL] [Abstract][Full Text] [Related]
17. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
[TBL] [Abstract][Full Text] [Related]
18. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Ozsu E; Cizmecioglu FM; Yesiltepe Mutlu G; Yuksel AB; Calıskan M; Yesilyurt A; Hatun S
Horm Res Paediatr; 2018; 90(4):257-265. PubMed ID: 30481753
[TBL] [Abstract][Full Text] [Related]
19. Mutations in HNF1A result in marked alterations of plasma glycan profile.
Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
[TBL] [Abstract][Full Text] [Related]
20. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
